Drug intelligence / Profile preview

ciprofloxacin + minocycline

Development stage: Preclinical
Lead developer: Bayer
Modality: Small Molecules
Administration: Oral, Intravenous, Topical

Overview

A combination antibiotic therapy consisting of ciprofloxacin (a fluoroquinolone antibiotic) and minocycline (a tetracycline antibiotic). This combination has been studied for its antimicrobial effects against various bacteria, including Elizabethkingia anophelis. In time-kill studies, the minocycline-ciprofloxacin combination has shown synergistic effects against certain bacteria, with a difference in CFU counts meeting the criteria of synergy in some cases. The combination has also been investigated for dental applications, particularly in treating infected root canals.

Targets

Bacterial RibosomeDNA gyrase

Beyond the preview

Go deeper on ciprofloxacin + minocycline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ciprofloxacin + minocycline.

Explore the full profile